DVC LVS

Drug Profile

DVC LVS

Latest Information Update: 21 Dec 2015

Price : $50

At a glance

  • Originator DynPort Vaccine Company LLC
  • Developer DynPort Vaccine Company; National Institute of Allergy and Infectious Diseases
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Tularaemia

Most Recent Events

  • 21 Dec 2015 No recent reports on development identified - Phase-II for Tularaemia (Prevention, In volunteers) in USA (Intradermal)
  • 03 Apr 2008 Tularaemia vaccine is still in clinical development
  • 28 Feb 2007 Phase-I clinical trials in Tularaemia in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top